|
[1]Chapman R, Fevery J, Kalloo A, et al.Diagnosis andmanagement of primary sclerosing cholangitis[J].Hepatology, 2010, 51 (2) :660-678.
|
|
[2]Dave M, Elmunzer BJ, Dwamena BA, et al.Primary sclerosingcholangitis:meta-analysis of diagnostic performance of MRcholangiopancreatography[J].Radiology, 2010, 256 (2) :387-396.
|
|
[3]European Association for the Study of the Liver.EASLclinical practice guidelines:management of cholestatic liverdiseases[J].J Hepatol, 2009, 51 (2) :237-267.
|
|
[4]Shi J, Li Z, Zeng X, et al.Ursodeoxycholic acid in primarysclerosing cholangitis:meta-analysis of randomized controlledtrials[J].Hepatol Res, 2009, 39 (9) :865-873.
|
|
[5]Sinakos E, Marschall HU, Lindor K, et al.Bile acid changes afterhigh-dose ursodeoxycholic acid treatment in primary sclerosingcholangitis:Relation to disease progression[J].Hepatology, 2010, 52 (1) :197-203.
|
|
[6]Barngarulingam SY, Bjornsson E, Enders F, et al.Long termoutcomes of positive fluorescence in situ hybridization (FISH) tests in primary sclerosing cholangitis[J].Hepatology, 2010, 51 (1) :174-180.
|
|
[7]Chapman WC.Fluorescent in situ hybridization testing in primarysclerosing cholangitis:useful testing or a random chanceresult[J].Hepatology, 2010, 51 (1) :16-19.
|
|
[8]Kaplan MM, Bonder A, Ruthazer R, et al.Methotrexate inpatients with primary biliary cirrhosis who respond incompletelyto treatment with ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (11) :3207-3217.
|
|
[9]Rabahi N, Chrétien Y, Gaouar F, et al.Triple therapy withursodeoxycholic acid, budesonide and mycophenolate mofetilin patients with features of severe primary biliary cirrhosis notresponding to ursodeoxycholic acid alone[J].Gastroenterol ClinBiol, 2010, 34 (4-5) :283-287.
|
|
[10]Levy C, Peter JA, Nelson DR, et al.Pilot study:fenofibratefor patients with primary biliary cirrhosis and an incompleteresponse to ursodeoxycholic acid[J].Aliment Pharmacol Ther, 2011, 33 (2) :235-342.
|
|
[11]Hazzan R, Tur-Kaspa R.Bezafibrate treatment of primary biliarycirrhosis following incomplete response to ursodeoxycholicacid[J].J Clin Gastroenterol, 2010, 44 (5) :371-373.
|
|
[12]Silveira MG, Brunt EM, Heathcote J, et al.American Associationfor the Study of Liver Diseases endpoints conference:designand endpoints for clinical trials in primary biliary cirrhosis[J].Hepatology, 2010, 52 (1) :349-359.
|
|
[13]Manns MP, Czaja AJ, Gorham JD, et al.Diagnosis andmanagement of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.
|
|
[14]Bjrnsson E, Talwalkar J, Treeprasertsuk S, et al.Drug-inducedautoimmune hepatitis:clinical characteristics and prognosis[J].Hepatology, 2010, 51 (6) :2040-2048.
|
|
[15]Umemura T, Zen Y, Hamano H, et al.IgG4 associated autoimmunehepatitis:a differential diagnosis for classical autoimmunehepatitis[J].Gut, 2007, 56 (10) :1471-1472.
|
|
[16]Chung H, Watanabe T, Kudo M, et al.Identification andcharacterization of IgG4-associated autoimmune hepatitis[J].Liver Int, 2010, 30 (2) :222-231.
|
|
[17]Umemura T, Zen Y, Hamano H, et al.Clinical significance ofimmunoglobulin G4-associated autoimmune hepatitis[J].JGastroenterol, 2011, 46 (Suppl 1) :48-55.
|
|
[18]Boberg KM, Chapman RW, Hirschfield GM, et al.Overlapsyndromes:The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J].JHepatol, 2011, 54 (2) :374-385.
|
DownLoad: